Breaking Finance News

Raymond James disclosed Spark Therapeutics (NDAQ:ONCE), hiking its price target to $96.00 earlier today

Yesterday Spark Therapeutics (NDAQ:ONCE) traded 0.00% even at $86.20. The company’s 50-day moving average is $85.91 and its 200-day moving average is $85.91. The last closing price is up 0.34% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 536,939 shares of the stock were exchanged, up from an average trading volume of 447,313

Reporting a potential upside of 0.11%, Raymond James raised the target price of Spark Therapeutics (NDAQ:ONCE) to $96.00

Previously on 10/06/2017, Goldman Sachs reported on Spark Therapeutics (NDAQ:ONCE) raised the target price from $0.00 to $111.00. At the time, this indicated a possible upside of 0.27%.

See Chart Below

Spark Therapeutics (NDAQ:ONCE)

Spark Therapeutics has a 52 week low of $35.07 and a 52 week high of $91.00 The company’s market cap is currently $0.

In addition to Raymond James reporting its target price, a total of 9 brokers have issued a report on the stock. The consensus target price is $58.44 with 0 brokers rating the stock a strong buy, 5 brokers rating the stock a buy, 3 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 1 broker rating the stock a sell.

General Information About Spark Therapeutics (NDAQ:ONCE)

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.